Carrier-free nano-prodrugs for minimally invasive cancer therapy-Reference-Cited by-同舟云学术

Carrier-free nano-prodrugs for minimally invasive cancer therapy

Published:2024 Issue:32 Volume:16 Page:15256-15264
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Tanita Keita¹,Koseki Yoshitaka¹²^ORCID,Kumar Sanjay¹,Taemaitree Farsai¹²,Mizutani Asuka¹,Nakatsuji Hirotaka¹,Suzuki Ryuju¹,Dao Anh Thi Ngoc³,Fujishima Fumiyoshi⁴,Tada Hiroshi⁵,Ishida Takanori⁵,Saijo Ken⁶⁷,Ishioka Chikashi⁶⁷,Kasai Hitoshi¹

Affiliation:

1. Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, 980-8577, Japan

2. Research Institute for Electronic Science, Hokkaido University, N20W10, Kita-ku, Sapporo, 001-0020, Japan

3. Graduate School of Engineering, Nagasaki University, 1-14 Bunkyo, Nagasaki, 852-8521, Japan

4. Department of Pathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan

5. Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, 980-8575, Japan

6. Department of Medical Oncology, Tohoku University Hospital, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan

7. Department of Clinical Oncology, Tohoku University Graduate School of Medicine, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan

Abstract

SNC4DC, a dimer of SN-38 derivatives, has been synthesized. SNC4DC nanoparticles called nano-prodrugs are internalized into the cell and dissociate, and the active SN-38 is released after reduction of the S–S bond in the presence of GSH occurs.

Funder

Japan Society for the Promotion of Science

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NR/D4NR01763C

Reference39 articles.

1. Chemotherapy Side-Effects: Not All DNA Damage Is Equal

2. Topoisomerase I inhibitors: camptothecins and beyond

3. Prodrug approach: An overview of recent cases

4. A hydrogen sulfide-responsive prodrug for monitoring real-time release and improving therapeutic effects of anticancer drug SN-38

5. In situ activation of therapeutics through bioorthogonal catalysis